Stockreport

Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366

Assembly Biosciences, Inc.  (ASMB) 
Last assembly biosciences, inc. earnings: 3/4 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.assemblybio.com/investor-relations
PDF – Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interim data expected in Q3 2024 – – Phase 1b [Read more]